(0.32%) 5 116.32 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.25%) $2.02
(0.29%) $2 354.10
(0.44%) $27.66
(4.16%) $960.50
(-0.26%) $0.932
(-0.45%) $10.98
(-0.57%) $0.796
(1.63%) $93.37
4 days till quarter result
(bmo 2024-05-03)
Expected move: +/- 12.02%
@ $7.86
発行日: 15 2月 2024 @ 05:07
リターン: -29.85%
前回のシグナル: 2月 15 - 02:00
前回のシグナル:
リターン: 1.62 %
Live Chart Being Loaded With Signals
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases...
Stats | |
---|---|
本日の出来高 | 547 331 |
平均出来高 | 1.92M |
時価総額 | 453.11M |
EPS | $0 ( 2024-02-28 ) |
次の収益日 | ( $-0.650 ) 2024-05-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.73 |
ATR14 | $0.00900 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-02 | Lucera Erick | Buy | 25 966 | Common Stock |
2024-03-02 | Lucera Erick | Buy | 35 300 | Common Stock |
2024-03-02 | Lucera Erick | Buy | 106 000 | Stock Option (right to buy) |
2024-03-02 | Burkly Linda | Buy | 15 055 | Common Stock |
2024-03-02 | Burkly Linda | Buy | 74 400 | Stock Option (right to buy) |
INSIDER POWER |
---|
88.69 |
Last 95 transactions |
Buy: 4 455 498 | Sell: 157 736 |
ボリューム 相関
Editas Medicine Inc 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Editas Medicine Inc 相関 - 通貨/商品
Editas Medicine Inc 財務諸表
Annual | 2023 |
収益: | $78.12M |
総利益: | $72.06M (92.24 %) |
EPS: | $-2.02 |
FY | 2023 |
収益: | $78.12M |
総利益: | $72.06M (92.24 %) |
EPS: | $-2.02 |
FY | 2022 |
収益: | $19.71M |
総利益: | $13.38M (67.85 %) |
EPS: | $-2.98 |
FY | 2021 |
収益: | $25.54M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.85 |
Financial Reports:
No articles found.
Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。